Aradigm

 

HomeAboutProductsTechnologiesInvestorsCareers

 

 

Leadership

About Aradigm

Business Overview

Pioneering Advancements in the Pulmonary
Pharmaceutical Industry

Aradigm's senior management team and the Board of Directors have in-depth expertise and experience in the management and oversight of public health care companies and in bringing a variety of pharmaceutical and health care products to market in the U.S. and internationally. Members of the company's Scientific Advisory Board are among the world's leading experts in pulmonary medicine and inhalation drug delivery. Together, this leadership team is pioneering important advancements in the respiratory sector of the pharmaceutical industry and positioning Aradigm as a new leader in the specialty pharmaceutical market.

 

Executive Management


 

John Siebert, Ph.D.
Executive Chairman

The Board of Directors appointed Dr. John Siebert, Chairman of the Board of the Company, as Executive Chairman and Interim Principal Executive Officer of the Company. Dr. Siebert has served as a director of the Company since November 2006.

Dr. Siebert was Chief Executive Officer of Chase Pharmaceuticals, a company conducting clinical trials in Alzheimer’s disease based on a unique hypothesis from May 2014 to November 2015. From 2010 to 2014, he was a Partner and Chief Operating Officer of New Rhein Healthcare Investors, LLC, a private equity group. From May 2003 to October 2008, Dr. Siebert was the Chairman and Chief Executive Officer of CyDex, Inc., a privately held specialty pharmaceutical company. From September 1995 to April 2003, he was President and Chief Executive Officer of CIMA Labs, Inc., a publicly traded drug delivery company, and from July 1995 to September 1995 he was President and Chief Operating Officer of CIMA Labs. From 1992 to 1995, Dr. Siebert was Vice President, Technical Affairs at Dey Laboratories, Inc., a privately held pharmaceutical company. From 1988 to 1992, Dr. Siebert headed R&D and Quality Control at a division of Bayer Corporation. Prior to that, Dr. Siebert was employed by E.R. Squibb & Sons, Inc., G.D. Searle & Co., Gillette and The Procter & Gamble Company. Dr. Siebert holds a B.S. in Chemistry from Illinois Benedictine University, an M.S. in Organic Chemistry from Wichita State University and a Ph.D. in Organic Chemistry from the University of Missouri. Dr. Siebert also serves on the Board of Directors of Supernus Pharmaceuticals, Inc., serving as a member of the Audit Committee and the Chair of the Compensation Committee.

 

 

Juergen Froehlich, MD, MBA, FCPh
Chief Medical Officer
Dr. Froehlich has more than 20 years of pharmaceutical industry experience in preclinical, clinical and regulatory activities at Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers Squibb, Ipsen and Vertex Pharmaceuticals. Dr. Froehlich was closely involved in the commercialization of various drugs and biologics and alliance activities with other companies. Dr. Froehlich graduated from the Medical School at Wuerzburg University in Germany. He is a Diplomate of the American Board of Clinical Pharmacology, a Fellow of the American College of Clinical Pharmacology and a Fellow of the Faculty of Pharmaceutical Medicine. He also holds a dual executive MBA degree from the Graduate School of Business Administration in Zurich, Switzerland and from the State University of New York at Albany.

 

 

David Cipolla, Ph.D.
Vice President Preclinical R&D
Dr. Cipolla holds a chemical engineering degree from MIT (S.B.) and UC Davis (M.S.) and a pharmacy degree from the University of Sydney (Ph.D.). Dr. Cipolla currently leads the preclinical research, pharmaceutical sciences and intellectual property efforts at Aradigm Corp and has served in various scientific and technical capacities at Aradigm since 1996.  Prior to joining Aradigm, Dr. Cipolla worked at Genentech, Inc. (1988-1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis.   Dr. Cipolla has contributed in a number of roles on pharmaceutical consortia (including chair of IPAC-RS), academic societies (ISAM board member) and on the editorial board of multiple scientific journals.

 

     

Board of Directors

Virgil D. Thompson
Chairman of the Board, Aradigm Corporation;
CEO of Spinnaker Biosciences, Inc.

Dr. John M. Siebert
Former Chairman & Chief Executive Officer, CyDex, Inc.;
Former CEO of CIMA Labs

Frederick Hudson
Director of Supernus Pharmaceuticals, Inc.;
Former partner of KPMG, LLP

Ed Gordon
Founder and Principal of 4c Advisors, LLC;
Former Director of Ladenburg Thalmann & Co., Inc.

Scientific Advisory Board
Aradigm's Scientific Advisory Board is a highly regarded team of scientific experts who help the Company with strategic input into the development of treatments for severe respiratory disease, and in pharmaceutical development and pulmonary drug delivery in general. The group assists the company on a variety of issues related to potential product applications, product development paths and clinical testing.

Peter R. Byron, Ph.D.
Medical College of Virginia, Virginia Commonwealth University
Expertise: Aerosol Science/Pharmaceutics

Stephen J. Farr, Ph.D.
Zogenix, Inc.
Expertise: Pulmonary Delivery/Pharmaceutics

Tunde Otulana , M.D.
Boehringer Ingelheim
Expertise: Pulmonary Medicine, Regulatory Science

Adam Wanner, Ph.D.
University of Miami
Expertise: Chronic Obstructive Pulmonary Disease (COPD)

In addition to this Scientific Advisory Board, the Company also engages other scientific and medical experts to assist on issues specific to particular indications and programs.

 

CONTACT NEWS & EVENTS LEGAL SITE MAP

©2018 Aradigm Corporation. All Rights Reserved.